Evidence map›Paper›PMID 30051179›Full record

Trial reportClinical research in cardiology : official journal of the German Cardiac Society2019

T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF.

Aurelija Abraityte, Pål Aukrust, Lei Kou, Inder S Anand, James Young, John J V Mcmurray, Dirk J van Veldhuisen, Lars Gullestad, Thor Ueland

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00358215 (A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00358215 phase3completednot on this map

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia

TypeinterventionalSponsorAmgenRan2006 to 2012Enrolled2,278ConditionsHeart Failure, Anemia, Cardiovascular Disease, Ventricular DysfunctionArmsDarbepoetin alfa, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Aurelija AbraityteResearch Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Nydalen, P. B. 4950, 0424, Oslo, Norway.
Pål AukrustResearch Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Nydalen, P. B. 4950, 0424, Oslo, Norway.
Lei KouCleveland Clinic Foundation, Cleveland, USA.
Inder S AnandVA Medical Center and University of Minnesota, Minneapolis, MN, USA.
James YoungCleveland Clinic Foundation, Cleveland, USA.
John J V McmurrayBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Dirk J van VeldhuisenUniversity Medical Center Groningen, Groningen, The Netherlands.
Lars GullestadDepartment of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Thor UelandResearch Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Nydalen, P. B. 4950, 0424, Oslo, Norway. thor.ueland@medisin.uio.no.ORCID http://orcid.org/0000-0001-5005-0784
Oslo University Hospital · NOCleveland Clinic · USUniversity Medical Center Groningen · NLUniversity of Glasgow · GBUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundActivated leukocytes may contribute to the development and progression of heart failure (HF). We investigated the predictive value of circulating levels of stable and readily detectable markers reflecting both monocyte/macrophage and T-cell activity, on clinical outcomes in HF patients with reduced ejection fraction (HFrEF).

methodsThe association between baseline plasma levels of soluble CD163 (sCD163), macrophage migration inhibitory factor (MIF), granulysin, soluble interleukin-2 receptor (sIL-2R), and activated leukocyte cell adhesion molecule (ALCAM) and the primary endpoint of death from any cause or first hospitalization for worsening of HF was evaluated using multivariable Cox proportional hazard models in 1541 patients with systolic HF and mild to moderate anemia, enrolled in the Reduction of Events by darbepoetin alfa in Heart Failure (RED-HF) trial. Modifying effects and interaction with darbepoetin alfa treatment were also assessed.

resultsAll leukocyte markers, except granulysin, were associated with the primary outcome and all-cause death in univariate analysis (all p < 0.01) and remained significantly associated in multivariable analysis adjusting for conventional clinical variables (e.g. age, gender, BMI, NYHA class, creatinine, LVEF, etiology) and CRP. However, after final adjustment for TnT and NT-proBNP no associations were found with outcomes. No interaction with darbepoetin alpha treatment was observed for any marker.

conclusionsLeukocyte activation markers sCD163, MIF, sIL-2R, and ALCAM were associated with adverse outcome in patients with HFrEF, but add little as prognostic markers on top of established biochemical risk markers. CLINICAL

trial registrationhttps://clinicaltrials.gov/ct2/show/NCT00358215 .

Indexed as

Activated-Leukocyte Cell Adhesion MoleculeAgedAnemiaAntigens, CDBiomarkersCell Adhesion Molecules, NeuronalDarbepoetin alfaFemaleFetal ProteinsHeart Failure, SystolicHematinicsHospitalizationHumansInjections, SubcutaneousIntramolecular OxidoreductasesMacrophage ActivationActivated-Leukocyte Cell Adhesion MoleculeALCAM protein, humanAntigens, CDBiomarkersCell Adhesion Molecules, NeuronalDarbepoetin alfaFetal ProteinsHematinicsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMIF protein, humanHeart failureLeukocyteMacrophageMonocytePrognosisT cell

Identifiers

PMID30051179
OpenAlexW2884386742

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.